| Ytd | 55.86% | |
| 1y | 203.32% |
| Open | 14.37 | Prev Close | 14.33 | Low | 14.20 | High | 14.72 | Mkt Cap | 913.12M |
| Vol | 0.00 | Avg Vol | 932.05K | EPS | -1.18 | P/E | -12.39 | Forward P/E | -5.13 |
| Beta | 1.83 | Short Ratio | 19.61 | Inst. Own | 56.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-28 | 50-d Avg | 12.65 | 200-d Avg | 10.84 | 1yr Est | 7.00 |
DSGN News
RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 we
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to ta
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clini
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ata
DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endo
CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clin
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investo
U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapir
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) have received an average recomm
CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clin
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) gapped up prior to trading on F
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report)'s stock price traded down 4.5% during mid
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clin
The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter re
https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday
Monday's session saw 114 companies set new 52-week lows.
On Monday, 89 stocks made new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
On Friday, 497 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.